A detailed history of State Of Wisconsin Investment Board transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 81,770 shares of PHAT stock, worth $613,275. This represents 0.0% of its overall portfolio holdings.

Number of Shares
81,770
Previous 113,592 28.01%
Holding current value
$613,275
Previous $1.17 Million 26.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.25 - $19.5 $326,175 - $620,529
-31,822 Reduced 28.01%
81,770 $1.48 Million
Q2 2024

Aug 14, 2024

BUY
$8.97 - $12.05 $488,021 - $655,592
54,406 Added 91.92%
113,592 $1.17 Million
Q1 2024

May 14, 2024

BUY
$6.21 - $11.05 $73,725 - $131,185
11,872 Added 25.09%
59,186 $628,000
Q4 2023

Feb 12, 2024

SELL
$6.99 - $10.71 $254,729 - $390,293
-36,442 Reduced 43.51%
47,314 $431,000
Q3 2023

Nov 14, 2023

SELL
$10.26 - $15.7 $26,050 - $39,862
-2,539 Reduced 2.94%
83,756 $868,000
Q2 2023

Aug 14, 2023

SELL
$7.28 - $14.32 $64,588 - $127,047
-8,872 Reduced 9.32%
86,295 $1.24 Million
Q1 2023

May 15, 2023

SELL
$6.19 - $12.36 $16,168 - $32,284
-2,612 Reduced 2.67%
95,167 $679,000
Q4 2022

Feb 14, 2023

BUY
$9.18 - $11.53 $101,815 - $127,879
11,091 Added 12.79%
97,779 $1.1 Million
Q3 2022

Nov 14, 2022

SELL
$6.46 - $12.11 $7,441 - $13,950
-1,152 Reduced 1.31%
86,688 $961,000
Q2 2022

Aug 15, 2022

BUY
$6.2 - $15.5 $269,948 - $674,870
43,540 Added 98.28%
87,840 $741,000
Q1 2022

May 13, 2022

BUY
$11.55 - $20.06 $339,570 - $589,764
29,400 Added 197.32%
44,300 $603,000
Q4 2020

Feb 03, 2021

SELL
$33.22 - $50.26 $59,796 - $90,468
-1,800 Reduced 10.78%
14,900 $495,000
Q1 2020

May 06, 2020

BUY
$24.65 - $42.83 $411,655 - $715,261
16,700 New
16,700 $431,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $294M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.